Approved Drug May Be Repurposed to Treat Tumors Resulting from NF2-Related Schwannomatosis
Mass General-led phase 2 clinical trial generates promising results for brigatinib as a treatment for the genetic condition, which is characterized by brain and nerve sheath tumors.
The experience was very good. Thank you.
Dr Plotkin is an amazing provider and an expert in his field.
Listens and explains well
There is not much more I can say. In the many years I have met with Dr. Plotkin and his staff have been wonderful. Thank you to everyone I deal with at MGH.
Dr. Plotkin is the best! He's kind, concerned and knowledgeable. While waiting for my MRI results is stressful, it's been a pleasure togo over them with him for the past 11 years.
Dr. Plotkin and [redacted] and others on the team have always been thorough in their examinations, deliberate in making sure I understood the issues in my care, and willing to give non-judgmental guidance in my decisions.
Very friendly and easy to talk to just a down to earth doctor
Reassuring.
I am grateful for my life, Dr. Plotkin has been with me on the journey.
Dr.Plotkin has been my neurologist for a very long time. His entire staff from the front desk,MA's, RN's and NP's always treats patients with the upmost respect,and compassion.